Logo

SIGA

SIGA Technologies, Inc.

SIGA

SIGA Technologies, Inc. • NASDAQ
$6.06 ▲ 0.33% (+0.02)
Market Cap $433.96 M
52w High $9.62
52w Low $4.95
Dividend Yield 0.60%
P/E 5.88
Volume 143.65K
Outstanding Shares 71.61M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.62M ▼ $11.84M ▲ $-6.366M ▼ -242.97% ▼ $-0.09 ▼ $-8.214M ▼
Q2-2025 $81.12M ▲ $9.886M ▲ $35.483M ▲ 43.741% ▲ $0.5 ▲ $47.411M ▲
Q1-2025 $7.041M ▼ $9.138M ▼ $-408.223K ▼ -5.798% ▼ $-0.01 ▼ $-2.12M ▼
Q4-2024 $81.469M ▲ $10.251M ▲ $45.76M ▲ 56.169% ▲ $0.64 ▲ $57.217M ▲
Q3-2024 $10.01M $7.847M $1.344M 13.426% $0.019 $542.087K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $171.956M ▼ $231.603M ▼ $28.124M ▲ $203.479M ▼
Q2-2025 $182.463M ▲ $235.33M ▼ $26.018M ▼ $209.312M ▼
Q1-2025 $162.271M ▲ $247.067M ▲ $30.935M ▲ $216.133M ▲
Q4-2024 $155.4M ▲ $244.337M ▲ $28.532M ▲ $215.805M ▲
Q3-2024 $99.27M $195.354M $25.912M $169.442M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-6.366M ▼ $-9.814M ▼ $-289.576K ▼ $-403.48K ▲ $-10.508M ▼ $-10.104M ▼
Q2-2025 $35.483M ▲ $63.085M ▲ $-1 ▲ $-42.893M ▼ $20.192M ▲ $63.085M ▲
Q1-2025 $-408.223K ▼ $7.062M ▼ $-24.893K ▼ $-166.193K ▼ $6.871M ▼ $7.037M ▼
Q4-2024 $45.76M ▲ $56.31M ▲ $-17.838K ▲ $-161.756K ▲ $56.131M ▲ $56.292M ▲
Q3-2024 $1.344M $-7.383M $-22.427K $-274.132K $-7.68M $-7.406M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product Sales and Supportive Services
Product Sales and Supportive Services
 $80.00M ▲$10.00M ▼$80.00M ▲$0 ▼
Research and Development
Research and Development
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement SIGA shows the profile of a small but consistently profitable specialty pharma company. Revenue has been relatively steady over the past several years, with only modest growth rather than rapid expansion. What stands out is that a large portion of sales turns into profit, suggesting a high‑margin product and fairly lean operating structure. Operating income and net income have both stayed comfortably positive through the whole period, and earnings per share have generally trended upward over time, even if there are year‑to‑year bumps. The main risk on the income statement is concentration: results depend heavily on one flagship product and on government procurement cycles, which can make future revenue inherently uneven even if the long‑term demand story is intact.

Balance Sheet

Balance Sheet The balance sheet looks conservative and low risk. SIGA holds a sizable cash position relative to its overall size and carries no debt, which gives it financial flexibility and resilience during any slow periods in government ordering or clinical development. Shareholders’ equity has been building over time, reflecting the company’s ability to retain earnings rather than constantly raising new capital. Overall, it reads as a company that is self‑funding, not overly stretched, and able to weather setbacks without needing urgent external financing, though its asset base is still relatively small compared with larger pharmaceutical peers.

Cash Flow

Cash Flow Cash flow performance is a strong point. The company has repeatedly generated positive cash from its core operations, and because its capital spending needs are minimal, most of that operating cash effectively becomes free cash flow. There is some variability from year to year, which is typical for a business tied to large contracts and stockpile orders, but the pattern is one of consistent cash generation rather than cash burn. This supports ongoing R&D, gives room to navigate contract timing, and reduces dependence on capital markets, though the underlying volatility risk in future cash flows remains tied to government procurement decisions.

Competitive Edge

Competitive Edge SIGA occupies a very specialized niche in health security. Its main product, TPOXX, is currently the only approved oral treatment for smallpox in the United States and has broader orthopoxvirus applications abroad. This sole‑source status with U.S. agencies gives SIGA a quasi‑monopoly position in its core market and creates a high barrier for new entrants, especially given the complexity of working under the FDA’s biodefense framework and the need to manage sensitive pathogens. Long‑standing relationships with U.S. and international health authorities further reinforce its position. The flip side is concentration risk: the business is heavily dependent on a single product category and on government budgets and policy priorities, rather than broad, diversified commercial demand.

Innovation and R&D

Innovation and R&D R&D is focused and tightly aligned with the existing franchise. SIGA is working to expand TPOXX’s uses, including prevention after exposure and broader treatment claims for mpox, which, if successful, could meaningfully widen its addressable market. It is also developing new formulations such as pediatric liquid versions to cover more patient groups. Beyond TPOXX, early‑stage work on monoclonal antibodies aims to build a second pillar in orthopoxvirus treatment and reduce reliance on a single molecule over time. These projects introduce the usual clinical, regulatory, and timing uncertainties, and outcomes of key trials and regulatory submissions, plus future BARDA and other government contracts, will be pivotal for the company’s longer‑term growth path.

Summary

Overall, SIGA combines a focused, high‑margin biodefense business with a cautious balance sheet and recurring, though potentially lumpy, cash generation. Its strength lies in a unique and defensible position around TPOXX and deep experience with government contracting, rather than in diversified mass‑market drug sales. The main strategic questions center on concentration risk and contract timing: how successfully it can broaden TPOXX’s indications, win and renew large government agreements, and advance new programs to diversify its portfolio. Execution on these fronts will likely determine whether the company remains a stable niche cash generator or evolves into a broader health security platform over the coming years.

NEWS

November 6, 2025 · 4:01 PM UTC

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025

Read more

October 30, 2025 · 7:30 AM UTC

SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results

Read more

September 11, 2025 · 8:05 AM UTC

Saskatchewan Indian Gaming Authority (SIGA) Modernizes Point-of-Sale and Inventory Operations Across Seven Casinos with Agilysys Solutions

Read more